Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

Chemotherapy. 2020;65(1-2):54-57. doi: 10.1159/000508556. Epub 2020 Jul 2.


Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.

Keywords: Adverse events; Bevacizumab; Endoscopic suture; Gastric perforation; Ovarian cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Bevacizumab / adverse effects*
  • Bevacizumab / therapeutic use
  • Endoscopy, Gastrointestinal
  • Female
  • Humans
  • Intestinal Perforation / diagnostic imaging
  • Intestinal Perforation / etiology*
  • Intestinal Perforation / surgery
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology
  • Tomography, X-Ray Computed


  • Antineoplastic Agents, Immunological
  • Bevacizumab